View:
United States securities and exchange commission logo
May 27, 2021
Stephen Gunstream
Chief Executive Officer
Alpha Teknova, Inc.
2290 Bert Dr.
Hollister, CA 95023
Re: Alpha Teknova, Inc.
Amendment No. 1 to
Draft Registration Statement on Form S-1
Submitted May 14,
2021
CIK No. 0001850902
Dear Mr. Gunstream:
We have reviewed your amended draft registration statement and
have the following
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.
Please respond to this letter by providing the requested
information and either submitting
an amended draft registration statement or publicly filing your
registration statement on
EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
believe an amendment is appropriate, please tell us why in your
response.
After reviewing the information you provide in response to these
comments and your
amended draft registration statement or filed registration statement, we
may have additional
comments.
Amendment No. 1 to Draft Registration Statement on Form S-1
Prospectus Summary
Overview, page 1
1. With reference to your
revised disclosure on page 106, please revise the Overview section
of the Prospectus
Summary to disclose the percentages of your customers that purchase
catalog, custom and
GMP-grade products, respectively.
Use of Proceeds, page 65
2. We note your response
to our prior comment 7. Please further revise your disclosure in the
prospectus to provide
the detail given in your response letter, which states that although
you intend to use the
proceeds of the offering for the purposes listed, the company is not
Stephen Gunstream
Alpha Teknova, Inc.
May 27, 2021
Page 2
able to quantify the approximate amount of the proceeds that will be
devoted to particular
uses because it has not made specific determinations regarding the amount
or type of any
such expenditure, and does not have agreements or commitments for any
material
acquisitions or investments at this time.
Business
Well Positioned in Rapidly Evolving Cell and Gene Therapy Market, page 102
3. Your graphic at the top of page 103 indicates that 29% of your accounts
are classified as
"custom formulations" and 9% of your accounts are classified as "Clinical
Solutions
(GMP)". However, your revised disclosure on page 106 states that 9% of
your customers
purchased custom products and fewer than 1% purchased GMP-grade products
based on
cumulative purchase data from 2018 to 2020. Please reconcile your
disclosure or advise.
Please also revise to disclose the relevant time periods for the
information presented in the
graphic.
You may contact Julie Sherman at 202-551-3640 or Mary Mast at
202-551-3613 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Alan Campbell at 202-551-4224 or Laura Crotty at 202-551-7614 with any
other
questions.
Sincerely,
FirstName LastNameStephen Gunstream
Division of
Corporation Finance
Comapany NameAlpha Teknova, Inc.
Office of Life
Sciences
May 27, 2021 Page 2
cc: Elizabeth A. Razzano
FirstName LastName